Ahịa ozugbo sitere na ụlọ ọrụ China CAS 1006376-62-0 (1R,2R) -2- (3,4-difluorophenyl) cyclopropane carboxaMide Hot Sale Stock

Ticagrelor bụ ọgwụ antiplatelet nke ọnụ, aha akara America ya bụ Brilinta, na aha akara Europe bụ Brilique. Ticagrelor bụ onye na-anabata platelet adenosine diphosphate (ADP) nke na-anata ihe mgbochi nke emere iji gbochie platelet ịrapara ọnụ na imepụta mkpụkọ ọbara nke nwere ike ibute nkụchi obi na ọrịa strok. Na United States, FDA kwadoro ticagrelor na July 2011 maka ọgwụgwọ ndị okenye nwere nnukwu ọrịa coronary syndrome (ACS). Data ụlọ ọgwụ na-egosi na ticagrelor dị irè karịa clopidogrel n'ibelata ọnwụ obi na ọ dịkarịa ala ọnwa 12 mgbe ihe omume ACS gasịrị. Tụkwasị na nke ahụ, ticagrelorChemicalbook nyekwara aka belata ịrị elu nke stent thrombosis (ST) na ndị ọrịa natara stents iji gwọọ ACS. Na June 2020, AstraZeneca kwupụtara na US Food and Drug Administration (FDA) akwadoro ọgwụ mgbochi mgbochi Brilinta (ticagrelor) maka ndị ọrịa nwere ọrịa akwara ọbara nwere nnukwu ihe ize ndụ (CAD) iji belata ihe egwu nke nkụchi obi mbụ. ma ọ bụ ihe ize ndụ nke ọrịa strok. Na Nọvemba 2020, AstraZeneca kwupụtara na US Food and Drug Administration (FDA) akwadola ihe ngosi ọhụrụ maka anticoagulant Brilinta (ticagrelor), yana aspirin, maka ọgwụgwọ ischemia. N'ime ndị ọrịa nwere ọrịa strok hemorrhagic ma ọ bụ ọgụ ọgụ ischemic dị elu (TIA), ọ na-ebelata ohere nke ọrịa strok na-esote.